Compare GSK plc (GSK) vs Victoria's Secret & Co (VSXY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Victoria's Secret & Co — how do they compare? GSK plc trades at $46.52 (market cap $91.88B), while Victoria's Secret & Co trades at $82.86 (market cap $6.91B). The key difference: GSK plc is far larger — about 13.3× Victoria's Secret & Co's market cap, and GSK plc pays a 3.9% dividend while Victoria's Secret & Co pays none. Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and Victoria's Secret & Co for 34 Days on average.
| GSK | VSXY | |
|---|---|---|
Market Cap | $91.88B | $6.91B |
Volume | 7,730,529 | 1,346,928 |
Sector | Health | Consumer Cyclical |
52-Week High | $61.18 | $99.97 |
52-Week Low | $43.24 | $28.25 |
Typical Hold Time | 93 Days | 34 Days |
Enterprise Value | $111.88B | $9.29B |
Dividend Yield | 3.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.50, down 1.11% with bearish technical signals, though RSI levels suggest potential oversold conditions. Fundamentally, the company shows strong profitability with 72.73% gross margins and consistent earnings beats, while maintaining a reasonable P/E of 14.89. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite facing an HIV patent cliff.
GSK presents a mixed investment case with strong fundamentals and pipeline growth offset by technical weakness and patent expiration risks. The company's £40B sales target and cost-saving initiatives provide upside potential, while analyst consensus leans cautious with 55% hold ratings. Key risks include execution of pipeline development and competitive pressures in core markets.
Victoria's Secret (VSXY) trades at $81.83, down 4.62% today, but maintains strong technical momentum with a bullish moving average signal. The company shows improving fundamentals with three consecutive quarterly earnings beats and a robust 45.27% ROE. Recent news highlights the fashion show expansion and omnichannel growth strategy driving international sales momentum. Cash flow projections for 2026 show significant improvement to $334M net cash flow, indicating stronger financial health ahead.
The stock presents a compelling opportunity with 60% analyst buy ratings and an $86.80 consensus target offering 6% upside. However, elevated valuation multiples and recent margin pressure require careful monitoring. The company's Path to Potential initiative shows promising traction, but execution risks and competitive retail pressures remain key considerations for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Victoria's Secret & Co
Victoria's Secret & Co is a specialty retailer of lingerie, pajamas, and beauty products with prestige fragrances and body care. It serves customers at its Lingerie and Beauty stores around the globe and online enabling them to shop the brand anywhere and anytime.
Read more on VSXY →
